Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDURE phase III trial of subcutaneous AIN457 for maintenance of quiescent non-infectious posterior-segment uveitis during immunosuppressive taper
2009-014835-19Phase 3Terminated
- Sponsor
- Novartis
- Start
- Dec 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in uveitis, panuveitis and cyclitis (4 arms), sponsored by Novartis. Primary endpoint: Maintenance of suppression of intraocular inflammation / prevention of recurrence. Started Dec 2009; status: terminated.
02
Drugs
secukinumab
03
Conditions
uveitispanuveitiscyclitis
Beyond the preview
Go deeper on 2009-014835-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014835-19.